Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

3,468JPY
22 Jan 2018
Change (% chg)

¥165 (+5.00%)
Prev Close
¥3,303
Open
¥3,305
Day's High
¥3,469
Day's Low
¥3,303
Volume
3,148,500
Avg. Vol
2,322,541
52-wk High
¥3,469
52-wk Low
¥2,284

Chart for

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.84
Market Cap(Mil.): ¥1,772,528.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.80

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Vernalis has entered into drug discovery collaboration with Daiichi Sankyo

* VERNALIS SAYS ‍HAS ENTERED INTO DRUG DISCOVERY COLLABORATION WITH DAIICHI SANKYO COMPANY, LIMITED UTILIZING VERNALIS' DRUG DISCOVERY PLATFORM​

13 Dec 2017

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-R&I affirms Daiichi Sankyo's rating at "AA" and says negative outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

01 Dec 2017

BRIEF-Daiichi Sankyo to merge with unit Asubio Pharma

* Says it will merge with wholly owned unit Asubio Pharma Co., Ltd., effective April 1, 2018

30 Nov 2017

BRIEF- Daiichi Sankyo to repurchase shares for up to 50 bln yen

* Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018

31 Oct 2017

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Says it will buy back up to 50 billion yen ($442 million) of stock through March 23 Further company coverage: ($1 = 113.1500 yen) (Reporting By Chris Gallagher)

31 Oct 2017

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage:

31 Oct 2017

BRIEF-Inovalon enters into agreement with Daiichi Sankyo Inc

* Inovalon announces agreement with daiichi sankyo, inc. To support outcomes-based contracting

21 Sep 2017

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

31 Aug 2017

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca , following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

31 Aug 2017

Earnings vs. Estimates